Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada

Sexually Transmitted Diseases

Volumn 39, Issue 4, 2012, Pages 260-267

  Tuite, Ashleigh R ^a   Jayaraman, Gayatri C ^b,c   Allen, Vanessa G ^d   Fisman, David N ^a,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

^e Department of Health Policy Management and Evaluation ^*  (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; GENITAL TRACT INFECTION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SCREENING;

ADOLESCENT; ADULT; CANADA; CHILD; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MODELS, THEORETICAL; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84858705340     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31824717ae     Document Type: Article

References (38)

1. Public Health Agency of Canada. Reported cases and rates of chlamydia by age group and sex, 1991 to 2009. Available at: http://www.phac-aspc.gc.ca/std- mts/sti-its-tab/chlamydia-eng.php. Accessed June 13, 2011.
2. Ota K, Tan D, Mishra S, et al. Sexually transmitted infections. In: Loeb M, Smaill F, Smieja M, eds. Evidence-Based Infectious Diseases, 2nd ed. Hoboken, NJ: BMJ/Wiley-Blackwell, 2009: 136-176.
3. Turner CF, Rogers SM, Miller HG, et al. Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA 2002; 287:726-733. (Pubitemid 34250458)
4. Public Health Agency of Canada. Report on sexually transmitted infections in Canada, 2008. Available at: http://www.phac-aspc. gc.ca/std-mts/report/sti- its2008/index-eng.php. Accessed September 1, 2011.
5. Goeree R, Gully PR. The burden of chlamydial and gonococcal infection in Canada. In: Ronald AR, Peeling RW, eds. Prevention of Infertility: Research Studies of the Royal Commission on New Reproductive Technologies. Ottawa, ON, Canada: Minister of Supply and Services Canada, 1993:29-76.
6. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections, 2008. Available at: http://www.phacaspc. gc.ca/std-mts/sti-its/guide-lignesdir-eng.php. Accessed June 13, 2011.
7. Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005; 192:1836-1844. (Pubitemid 41587838)
8. Low N. Screening programmes for chlamydial infection: When will we ever learn? BMJ 2007; 334:725-728. (Pubitemid 46623736)
9. Fisman DN, Spain CV, Salmon ME, et al. The Philadelphia High-School STD Screening Program: Key insights from dynamic transmission modeling. Sex Transm Dis 2008; 35(Suppl 11):S61-S65.
10. Pinkerton SD. Sexual risk compensation and HIV/STD transmission: Empirical evidence and theoretical considerations. Risk Anal 2001; 21:727-736. (Pubitemid 34101539)
11. Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005; 192:1836-1844. (Pubitemid 41587838)
12. Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost-effectiveness analysis. Ann Intern Med 2004; 141:501-513.
13. Golden MR, Hogben M, Handsfield HH, et al. Partner notification for HIV and STD in the United States: Low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003; 30:490-496. (Pubitemid 36667028)
14. Tao G, Tian LH, Peterman TA. Estimating Chlamydia screening rates by using reported sexually transmitted disease tests for sexually active women aged 16 to 25 years in the United States. Sex Transm Dis 2007; 34:180-182. (Pubitemid 46673223)
15. Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: A review of human studies. J Infect Dis 2010; 201(suppl 2):S104-S113.
16. Watson EJ, Templeton A, Russell I, et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: A systematic review. J Med Microbiol 2002; 51:1021-1031. (Pubitemid 36020722)
17. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: The POPI (prevention of pelvic infection) trial. BMJ 2010; 340:c1642.
18. Risser WL, Risser JM. The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: A structured review. Int J STD AIDS 2007; 18:727-731. (Pubitemid 351738875)
19. Haggerty CL, Gottlieb SL, Taylor BD, et al. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201(suppl 2):S134-S155.
20. Mehta SD, Bishai D, Howell MR, et al. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83-91. (Pubitemid 34163704)
21. Stamm WE, Koutsky LA, Benedetti JK, et al. Chlamydia trachomatis urethral infections in men. Prevalence, risk factors, and clinical manifestations. Ann Intern Med 1984; 100:47-51. (Pubitemid 14219128)
22. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: A meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497-502. (Pubitemid 35001337)
23. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011; 52: 163-170.
24. Smith KJ, Tsevat J, Ness RB, et al. Quality of life utilities for pelvic inflammatory disease health states. Sex Transm Dis 2008; 35:307-311. (Pubitemid 351619537)
25. Appendix 2: Chlamydia. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Acadamy Press, 2000:149-158.
26. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19. (Pubitemid 38252839)
27. Cohen H. Drug Topics Red Book. Montvale, NJ: Thompson PDR, 2003.
28. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-1258. (Pubitemid 26337709)
29. Rank RG, Whittum-Hudson JA. Protective immunity to chlamydial genital infection: Evidence from animal studies. J Infect Dis 2010; 201(suppl 2):S168-S177.
30. Batteiger BE, Xu F, Johnson RE, et al. Protective immunity to Chlamydia trachomatis genital infection: Evidence from human studies. J Infect Dis 2010; 201(suppl 2):S178-S189.
31. Statistics Canada. The Consumer Price Index. Catalogue no. 62-001-X 2010; 89. Available at: www.statcan.gc.ca/pub/62-001-x/62-001-x2010012-eng.pdf. Accessed January 11, 2011.
32. Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect 2007; 83:267-274. (Pubitemid 47242502)
33. Centers for Disease Control and Prevention. Chlamydia breeds serious consequences. Available at: http://www.cdc.gov/Partners/Archive/Chlamydia/index. html. Accessed March 17, 2011.
34. French CE, Hughes G, Nicholson A, et al. Estimation of the rate of pelvic inflammatory disease diagnoses: Trends in England, 2000-2008. Sex Transm Dis 2011; 38:158-162.
35. Brown AE, Sadler KE, Tomkins SE, et al. Recent trends in HIV and other STIs in the United Kingdom: Data to the end of 2002. Sex Transm Infect 2004; 80:159-166. (Pubitemid 38746189)
36. Bohm MK, Newman L, Satterwhite CL, et al. Pelvic inflammatory disease among privately insured women, United States, 2001-2005. Sex Transm Dis 2010; 37:131-136.
37. Owusu-Edusei K, Jr, Bohm MK, Chesson HW, et al. Chlamydia screening and pelvic inflammatory disease: Insights from exploratory time-series analyses. Am J Prev Med 2010; 38:652-657.
38. Golden MR, Hughes JP, Brewer DD, et al. Evaluation of a population-based program of expedited partner therapy for gonorrhea and chlamydial infection. Sex Transm Dis 2007; 34:598-603. (Pubitemid 47207151)